Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.

ABSTRACT:

Introduction

Upadacitinib, an oral selective-JAK1 inhibitor, has been used in clinical trials to treat atopic dermatitis (AD).

Aim

To evaluate the efficacy and safety of upadacitinib in moderate-to-severe AD.

Material and methods

We searched clinical trials from PubMed, Embase, Cochrane Library databases, and Web of Science. All randomized controlled trials (RCTs) of upadacitinib treatment on patients with moderate-to-severe AD were included. A meta-analysis was performed using the fixed- or random-effects models to calculate pooled standard mean differences or relative risks (SMD or RR, respectively).

Results

Compared with the placebo group, our meta-analysis revealed that upadacitinib was related to a significant decrease in Eczema Area and Severity Index (EA

SUBMITTER: Huang Y 

PROVIDER: S-EPMC10809830 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature